NCT03842202

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine. In addition, the study will also look at the effect of semaglutide on the participant's appetite and energy intake. Participants will either get semaglutide or "dummy" medicine - which treatment any participant gets is decided by chance. Participants will take 1 injection per week. The study medicine is injected with a thin needle in the stomach, thigh or upper arm. The study will last for about 27 weeks (from first treatment to last check-up). Participants will have 8 visits at the clinic with the study doctor.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide	Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
DRUG	Placebo	Participants will receive once weekly injections of semaglutide matched placebo.

Timeline

• Start date: 2019-02-15
• Primary completion: 2019-11-04
• Completion: 2019-11-04
• First posted: 2019-02-15
• Last updated: 2020-12-24

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study